Premium
Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 Expression Using Targeted Contrast‐Enhanced High‐Frequency Ultrasonography
Author(s) -
Lyshchik Andrej,
Fleischer Arthur C.,
Huamani Jessica,
Hallahan Dennis E.,
Brissova Marcela,
Gore John C.
Publication year - 2007
Publication title -
journal of ultrasound in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.574
H-Index - 91
eISSN - 1550-9613
pISSN - 0278-4297
DOI - 10.7863/jum.2007.26.11.1575
Subject(s) - medicine , in vivo , vascular endothelial growth factor , pathology , monoclonal antibody , ultrasound , immunohistochemistry , immunocytochemistry , kinase insert domain receptor , isotype , antibody , cancer research , radiology , vascular endothelial growth factor a , vegf receptors , immunology , biology , microbiology and biotechnology
Objectives The aim of our study was to investigate the use of targeted contrast‐enhanced high‐frequency ultrasonography for molecular imaging of vascular endothelial growth factor receptor 2 (VEGFR2) expression on tumor vascular endothelium in murine models of breast cancer. Methods Highly invasive metastatic (4T1) and nonmetatstatic (67NR) breast cancer cells were implanted in athymic nude mice. Tumors were examined in vivo with targeted contrast‐enhanced high‐frequency ultrasonography using a scanner with a 40‐MHz probe. Randomized boluses of ultrasound contrast agents (UCAs) conjugated with an anti‐VEGFR2 monoclonal antibody or an isotype control antibody (immunoglobulin G) were injected into the animals. Sonograms were analyzed by calculation of the normalized video intensity amplitudes caused by backscatter of the bound UCA. After ultrasonography, the tumor samples were harvested for analysis of VEGFR2 expression by immunoblotting and immunocytochemistry. Results The mean video intensity amplitude caused by backscatter of the retained VEGFR2‐targeted UCA was significantly higher than that of the control UCA (mean ± SD: 4T1 tumors, 15 ± 3.5 versus 7 ± 1.6 dB; P < .01; 67NR tumors, 50 ± 12.3 versus 12 ± 2.6 dB; P < .01). There was a significant difference in VEGFR2‐targeted UCA retention between 4T1 and 67NR tumors (normalized video intensity amplitudes, 15 ± 3.5 and 50 ± 12.3 dB, respectively; P < .001), and this correlated well with relative VEGFR2 expression in the two tumor types. Conclusions Targeted contrast‐enhanced high‐frequency ultrasonography may enable in vivo molecular imaging of VEGFR2 expression on the tumor vascular endothelium and may be used for noninvasive longitudinal evaluation of tumor angiogenesis in preclinical studies.